Ashion Analytics Revenue and Competitors

Ashion is a wholly owned subsidiary of the Translational Genomics Research Institute (TGen), commercializing TGen precision medicine technologies for the betterment of cancer patients worldwide. Through its CAP accredited and CLIA certified laboratory, Ashion brings together cutting-edge genomics and bioinformatics technologies with proprietary clinical knowledge bases to help oncologists identify potentially beneficial molecularly-targeted therapies and clinical trials for their patients care. Ashion is a startup company headquartered in Phoenix, Arizona. Leveraging years of scientific and clinical experience, Ashion was founded in 2014 when Translational Genomics Research Institute’s (TGen®) CLIA certified clinical sequencing laboratory became Ashion. Ashion continues work with TGen to provide clinical genomic sequencing for several important clinical research studies. In addition to national partnerships with hospitals, practices and payers, we currently serve several externally funded molecular profiling clinical studies (pancreatic cancer, melanoma, multiple myeloma, neuroblastoma, lung cancer, brain cancer and pediatric cancers). We continue to respond to healthcare providers’ and researchers’ needs by enhancing and developing tests that will support their efforts to offer individualized treatment options. Ashion offers a variety of tests and services, including large panel tests, whole exome sequencing and RNA sequencing in addition to research and drug development support.